Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biologic Therapy in Rare Eosinophil-Associated Disorders: Remaining Questions and Translational Research Opportunities.
Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, Johansson MW, Mathur SK, Ogbogu PU, Spencer LA, Wechsler ME, Zimmermann N, Klion AD; International Eosinophil Society Clinical Research Interest Group. Khoury P, et al. J Leukoc Biol. 2024 Mar 8:qiae051. doi: 10.1093/jleuko/qiae051. Online ahead of print. J Leukoc Biol. 2024. PMID: 38457125
Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory.
Gervais A, Dirksen EHC, Pohl T, Bechtold-Peters K, Burkitt W, D'Alessio V, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L. Gervais A, et al. Among authors: o riordan t. Eur J Pharm Biopharm. 2023 Oct;191:57-67. doi: 10.1016/j.ejpb.2023.08.008. Epub 2023 Aug 13. Eur J Pharm Biopharm. 2023. PMID: 37582411 Free article.
Technical considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory.
Pohl T, Gervais A, Dirksen EHC, D'Alessio V, Bechtold-Peters K, Burkitt W, Cao L, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L. Pohl T, et al. Among authors: o riordan t. Eur J Pharm Biopharm. 2023 Jul;188:231-242. doi: 10.1016/j.ejpb.2023.04.024. Epub 2023 May 3. Eur J Pharm Biopharm. 2023. PMID: 37146738 Free article.
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID. Busse WW, et al. Among authors: o riordan t. Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25. Lancet Respir Med. 2021. PMID: 34181876
Engaging people with lived experience in the grant review process.
Rittenbach K, Horne CG, O'Riordan T, Bichel A, Mitchell N, Fernandez Parra AM, MacMaster FP. Rittenbach K, et al. Among authors: o riordan t. BMC Med Ethics. 2019 Dec 16;20(1):95. doi: 10.1186/s12910-019-0436-0. BMC Med Ethics. 2019. PMID: 31842842 Free PMC article.
126 results